Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07340216 · ClinicalTrials.gov registry record · Phase 1
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
A Phase 1 study of Psoriasis, sponsored by Arcutis Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 5
- Study locations
NCT07340216 is a Phase 1 study of Psoriasis that is actively recruiting participants, run by Arcutis Biotherapeutics. The registered enrollment target is 16 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT07340216, a Phase 1 study of Psoriasis, is actively recruiting participants, sponsored by Arcutis Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
Conditions Studied
Interventions
- DRUG ARQ-154 Foam 0.3%
Study Locations (5)
Arkansas
- Arcutis Clinical Study Site 106 - Bryant
Florida
- Arcutis Clinical Study Site 107 - Miami Lakes
Idaho
- Arcutis Clinical Study Site 108 - Meridian
Indiana
- Arcutis Clinical Study Site 105 - West Lafayette
Texas
- Arcutis Clinical Study Site 104 - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07340216
The ClinicalTrials.gov registry entry for NCT07340216 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (97% lower). The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ARQ-154 Foam 0.3% is the first listed.
NCT07340216 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT07340216 about?
NCT07340216 is a clinical study titled "Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis". This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
What is the current status of trial NCT07340216?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-12-15. Estimated completion is 2027-02.
What conditions does trial NCT07340216 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT07340216?
The interventions under investigation include: ARQ-154 Foam 0.3% (DRUG).
Who is sponsoring clinical trial NCT07340216?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07340216 being conducted?
This trial has 5 study locations across Arkansas, Florida, Idaho, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.